ClinicalTrials.gg
CompletedNCT03532412Updated Dec 15, 2023

Different Loop Gain Phenotypes in Patients With Chronic Systolic Heart Failure and Periodic Breathing

An observational study in Periodic Breathing, sponsored by Wissenschaftliches Institut Bethanien e.V. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
12
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Sleep Apnea Syndromes with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea Syndromes · Germany.

Enrollment
27th of 29
12 · median 200
Started
2016
with 7 others
Observational
29 of 58
4 open now
Registered
48th of 58
by date
Lead sponsor
3 of 58
Wissenschaftliches Institut Bethanien e.V

Among the 58 studies in Sleep Apnea Syndromes with a site in Germany, this one is the 27th largest by enrollment of the 29 observational ones that give a count, is one of 8 that started in 2016, is one of 29 observational ones, and was the 48th registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

4 of the 58 studies in Sleep Apnea Syndromes with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sleep Apnea Syndromes with a site in Germany, or all of them as a file.
02

Study summary

Central sleep apnoea (CSA) is common in patients with chronic systolic heart failure (HFrEF). Various trials have shown a prevalence of 21 - 37% in this group of people. Up to 66% of patients with CSA and HFrEF present with periodic breathing (PB), which is considered being a marker of HF severity and poor prognosis. Brack et al. summarized data from cohorts, longitudinal studies and retrospective analyses showing an independently increased risk of death in HF patients with PB (HR 2.1-5.7 in five of seven studies). Furthermore, PB in HF patients is known to reduce quality of life and exercise performance and to increase sympathetic nerve activity as well as the probability of malignant cardiac arrhythmias.

The pathogenesis of PB is characterized by an instability of ventilatory drive. The level of carbon dioxide (CO2) in blood and cerebrospinal fluid correlates linearly with minute ventilation. A high level of CO2 increases ventilation while hypocapnia dampens it. This control theory is based on the loop gain (LG), which represents the sensitivity and reactivity of the ventilatory system and comprises three components: The plant gain defines the capacity of the system to change PaCO2 in response to a change in ventilation (metabolic response). It is influenced by the lung volume as well as the anatomy of the thorax and the upper airways. The feedback gain is defined by the chemoreceptor responsiveness in reaction to blood gas changes. The controller gain is represented by the respiratory control center in the brain stem and defines the capacity of the system to change ventilation in response to a change in PaCO2 (ventilatory response).

Sands et al. proposed and validated a mathematical model based on the ventilatory cycle pattern that quantifies the feedback loop. The ratio of ventilatory and cycle duration within the PB pattern is defined as the duty ratio (DR), which is the basis to calculate the LG. Any temporary breathing disturbance causing a PB pattern with a LG \< 1 stabilizes within a few breathing cycles. A LG > 1 represents an unstable ventilatory response and slight changes of CO2 are accompanied by overshooting and undershooting of the ventilation. In that case, the polysomnography shows the typical pattern of waxing and waning of the tidal volume and effort.

HF patients typically present with an increased LG due to an impaired left ventricular function and a hyperstimulation of pulmonary vagal receptors. Furthermore, Khoo showed an increased chemosensitivity (controller gain) as well as a decreased ventilatory capacity (plant gain) in this group of people.

Sands and colleagues characterized PB considering the mean LG derived from several ventilatory cycles during non-REM sleep. This retrospective study of PB in HFrEF patients addresses the following questions:

  1. Is a single LG value appropriate to characterize the individual PB?
  2. Does the LG depend on sleep stage and body position?
  3. Does the intraindividual LG variability allow for the discrimination of different PB phenotypes and, if so, do these phenotypes differ in further characteristics?
03

Conditions studied

  • Periodic Breathing

Keywords

  • Polysomnography, Sleep apnea, Central sleep apnea
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted to the sleep lab for diagnostic polysomnography.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systolic heart failure with left-ventricular \<45%
  • Apnea-Hypopnea index >15 per hour as determined by diagnostic polysomnography
  • Predominant central sleep apnea as defined by >50% central respiratory events

Exclusion criteria

Exclusion Criteria:

  • \<50 evaluable respiratory events for loop gain analysis during diagnostic polysomnography
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
12 participants (actual)
Patient registry
No

Groups and cohorts

  • HF+CSA+PB

    Systolic heart failure with predominant central sleep apnea and periodic breathing

06

What researchers measure

Primary outcomes

  1. Loop Gain

    Mathematically determined loop gain of periodic breathing according to Sands et al. \[10\] based on diagnostic polysomnography

    Time frame: During one day of diagnostic polysomnography

07

Study locations

1 site
  • Wissenschaftliches Institut Bethanien für Pneumologie e.V.
    Solingen, 42699, Germany
08

References and documents

Publications

  • Brack T, Randerath W, Bloch KE. Cheyne-Stokes respiration in patients with heart failure: prevalence, causes, consequences and treatments. Respiration. 2012;83(2):165-76. doi: 10.1159/000331457. Epub 2011 Oct 18. PubMed 22025128 ↗
  • Javaheri S, Shukla R, Zeigler H, Wexler L. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol. 2007 May 22;49(20):2028-34. doi: 10.1016/j.jacc.2007.01.084. Epub 2007 May 4. PubMed 17512359 ↗
  • Naughton MT. Epidemiology of central sleep apnoea in heart failure. Int J Cardiol. 2016 Mar;206 Suppl:S4-7. doi: 10.1016/j.ijcard.2016.02.125. Epub 2016 Feb 26. PubMed 26948168 ↗
  • Randerath W, Verbraecken J, Andreas S, Arzt M, Bloch KE, Brack T, Buyse B, De Backer W, Eckert DJ, Grote L, Hagmeyer L, Hedner J, Jennum P, La Rovere MT, Miltz C, McNicholas WT, Montserrat J, Naughton M, Pepin JL, Pevernagie D, Sanner B, Testelmans D, Tonia T, Vrijsen B, Wijkstra P, Levy P. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017 Jan 18;49(1):1600959. doi: 10.1183/13993003.00959-2016. Print 2017 Jan. PubMed 27920092 ↗
  • Yumino D, Bradley TD. Central sleep apnea and Cheyne-Stokes respiration. Proc Am Thorac Soc. 2008 Feb 15;5(2):226-36. doi: 10.1513/pats.200708-129MG. PubMed 18250216 ↗
  • Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 2012 Sep 18;126(12):1495-510. doi: 10.1161/CIRCULATIONAHA.111.070813. No abstract available. PubMed 22988046 ↗
  • Rowley JA, Badr MS. Central Sleep Apnea in Patients with Congestive Heart Failure. Sleep Med Clin. 2017 Jun;12(2):221-227. doi: 10.1016/j.jsmc.2017.03.001. PubMed 28477776 ↗
  • Naughton MT. Loop gain in apnea: gaining control or controlling the gain? Am J Respir Crit Care Med. 2010 Jan 15;181(2):103-5. doi: 10.1164/rccm.200909-1449ED. No abstract available. PubMed 20053968 ↗
  • Wellman A, Malhotra A, Fogel RB, Edwards JK, Schory K, White DP. Respiratory system loop gain in normal men and women measured with proportional-assist ventilation. J Appl Physiol (1985). 2003 Jan;94(1):205-12. doi: 10.1152/japplphysiol.00585.2002. Epub 2002 Sep 20. PubMed 12391042 ↗
  • Sands SA, Edwards BA, Kee K, Turton A, Skuza EM, Roebuck T, O'Driscoll DM, Hamilton GS, Naughton MT, Berger PJ. Loop gain as a means to predict a positive airway pressure suppression of Cheyne-Stokes respiration in patients with heart failure. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1067-75. doi: 10.1164/rccm.201103-0577OC. PubMed 21816941 ↗
  • Khoo VS. MRI--"magic radiotherapy imaging" for treatment planning? Br J Radiol. 2000 Mar;73(867):229-33. doi: 10.1259/bjr.73.867.10817036. No abstract available. PubMed 10817036 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Nov 2016, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2018
First posted
May 22, 2018
StartActual
Jun 28, 2016
Primary completionActual
Nov 14, 2016
CompletionActual
Nov 14, 2016
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03532412
Lead sponsor
Wissenschaftliches Institut Bethanien e.V
Responsible party
Sponsor
First posted
May 22, 2018
Start date
Jun 28, 2016
Primary completion
Nov 14, 2016
Completion
Nov 14, 2016
Last update
Dec 15, 2023

Study contacts

Winfried J Randerath, Prof. Dr.
principal investigator · Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion